Trial NCT05158855
Publication Sung J, Vaccines, 2022
Primary outcome on the report: During the blood sampling period, primary safety end points were assessed, including not only local reactions and systemic events, but also unsolicited adverse events and serious adverse events; All participants were observed for 1 h after the administration of booster or placebo to identify any immediate adverse events. Furthermore, 5 mL blood samples were drawn on days 0, 14, 35 and 49 for safety and immunogenicity assessments.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.